Show simple item record

dc.contributor.authorMateo, J
dc.contributor.authorMoreno, V
dc.contributor.authorGupta, A
dc.contributor.authorKaye, S
dc.contributor.authorDean, Emma J
dc.contributor.authorMiddleton, M
dc.contributor.authorFriedlander, M
dc.contributor.authorGourley, C
dc.contributor.authorPlummer, R
dc.contributor.authorRustin, G
dc.contributor.authorSessa, C
dc.contributor.authorLeunen, K
dc.contributor.authorLedermann, J
dc.contributor.authorSwaisland, H
dc.contributor.authorFielding, A
dc.contributor.authorBannister, W
dc.contributor.authorNicum, S
dc.contributor.authorMolife, L
dc.date.accessioned2016-06-24T12:11:17Z
dc.date.available2016-06-24T12:11:17Z
dc.date.issued2016-06
dc.identifier.citationAn adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. 2016, 11 (3):401-15 Target Oncolen
dc.identifier.issn1776-260X
dc.identifier.pmid27169564
dc.identifier.doi10.1007/s11523-016-0435-8
dc.identifier.urihttp://hdl.handle.net/10541/614533
dc.description.abstractOlaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation.
dc.language.isoenen
dc.rightsArchived with thanks to Targeted oncologyen
dc.titleAn adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib.en
dc.typeArticleen
dc.contributor.departmentDrug Development Unit, The Royal Marsden/The Institute of Cancer Research, Downs Road, Sutton, SM2 5PT, UKen
dc.identifier.journalTargeted Oncologyen
html.description.abstractOlaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation.


This item appears in the following Collection(s)

Show simple item record